CHINESE JOURNAL OF MEDICINAL GUIDE >
Expert Consensus on Auxiliary Examination and Therapeutic Effect Evaluation of Community-Acquired Pneumonia
2.Department of Neonatologya， Department of Pharmacy Dispensing Sectionb， Department of Neurology Ward 4c， Department of Songbei General Surgeryd， Department of Thoracic Surgerye Department of Songbei Oncologyf， the Fourth Affiliated Hospital of Harbin Medical University， Heilongjiang Harbin 150001， China； 3.Department of Neonatology， the Fifth Affiliated Hospital of Zunyi Medical University （Zhuhai）， Guangdong Zhuhai 519100， China；
4.Department of Geriatrics， Shenzhen People's Hospital，Guangdong Shenzhen 518020， China；
5.Department of Clinical Laboratory， the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine， Shandong Jinan 250031， China
Received date: 2026-02-06
Revised date: 2026-05-19
Accepted date: 2026-06-28
Online published: 2026-08-17
Community-acquired pneumonia （CAP） has become a global public health challenge due to its high incidence and mortality rate. The complex composition of its pathogen and diverse clinical manifestations pose significant challenges for early diagnosis and precise treatment of CAP. Currently， the value of auxiliary examinations（including radiological imaging， microbiological testing， and biomarker dynamic monitoring） in CAP diagnosis， treatment adjustment， and prognostic evaluation has not yet been fully realized.Although there are relevant diagnosis and treatment guidelines to follow， in clinical practice， in terms of the reasonable selection， standardized operation， result interpretation and systematic efficacy evaluation of auxiliary examinations， there is still a lack of unified and operational standards， which leads to inconsistency in diagnosis and treatment practices and restricts the improvement of medical quality and the efficient utilization of resources. To provide a practical and standardized reference framework for CAP auxiliary examinations and efficacy evaluation， the research team has invited experts from various fields to jointly write the "Expert Consensus on Auxiliary Examinations and Efficacy Evaluation of Community-Acquired Pneumonia （CAP）". Focusing on the two core aspects of CAP management （auxiliary examinations and efficacy evaluation）， this study systematically integrate the best available evidence and clinical experience to help clinicians more accurately assess the condition and optimize treatment decisions. At the same time， it lays the foundation for subsequent clinical practice and research in this field. The core recommendations include： based on disease severity stratification， the imaging examination pathway should be constructed， the indications and operation specifications of microbiological examination in different clinical scenarios should be clarified， the dynamic application of biomarkers in diagnosis and treatment monitoring should be standardized， and a structured efficacy evaluation system integrating clinical symptoms， laboratory indicators and imaging manifestations should be established， while pharmaceutical care and rational drug use guidance should be included. It covers the selection and adjustment of antibacterial drugs， therapeutic drug monitoring and adverse reaction management， and establishes a systematic auxiliary examination and etiological screening process for case of treatment failure.
YANG Yang, GAO Yue, WANG Linna, DAI Huiyu, YANG Fang, WANG Bo, XIA Lu, HAN Jingquan, YANG Haipeng, YU Chengyuan, CUI Yufan, TENG Yang
.
Expert Consensus on Auxiliary Examination and
Therapeutic Effect Evaluation of Community-Acquired Pneumonia
［1］ Oliveira E Silva PG， Cerqueira Batista Filho LA， Ismael PF， et al. Community-acquired pneumonia： epidemiology， diagnosis， prognostic severity scales， and new therapeutic options［J］.Medwave， 2023，23（11）：e2719.
［2］ Elias C， Nunes MC， Saadatian-Elahi M. Epidemiology of community-acquired pneumonia caused by S treptococcus pneumoniae in older adults：a narrative review［J］.Curr Opin Infect Dis， 2024，37（2）：144-153.
［3］ 宁璞，郑雅莉，高占成.基于UPLC-MS/MS的不同病原体感染社区获得性肺炎患者血清代谢组学特征谱分析［J］.国际呼吸杂志，2024，44（11）：1285-1297.
［4］ 何裕畅，叶志辉，张秀莲，等.老年社区获得性肺炎的临床表现与治疗研究进展［J］.中国防痨杂志，2024，46（S2）：520-521.
［5］ 中国医师协会急诊医师分会，中国急诊专科医联体，北京急诊医学学会. 急诊成人社区获得性肺炎临床实践指南（2024年版）［J］.中华急诊医学杂志，2025，34（3）：300-317.
［6］ Metlay JP， Waterer GW， Long AC，et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America［J］.Am J Respir Crit Care Med， 2019，200（7）：e45-e67.
［7］ European Society for Medical Oncology. ESMO guidelines methodology［EB/OL］.（2023-10-04）［2025-12-06］.http：//www.esmo.org/Guidelines/ESMO-Guidelines-Methodology.
［8］ 魏子伊，汤奕，滕泽，等.胸部X线片人工智能联邦学习系统用于病原学诊断儿童社区获得性肺炎［J］.中国介入影像与治疗学，2024，21（6）：368-373.
［9］ Eilat-Tsanani S， Kasher C， Levine-Kremer H. Community-acquired pneumonia-use of chest X-rays for diagnosis in family practice［J］.BMC Prim Care，2022，23（1）：271.
［10］ 张禹，陈婷婷，张茜，等.多重耐药细菌性医院获得性肺炎与呼吸机相关性肺炎的CT征象探讨［J］.临床放射学杂志，2020，39（10）：1967-1970.
［11］ 熊天波，宁燕，陈瑜莉，等.床旁超声对社区获得性肺炎老年患者的诊断价值［J］.分子影像学杂志，2021，44（4）：673-677.
［12］ Jones BE， Ramirez JA， Oren E， et al. Diagnosis and management of community-acquired pneumonia： an official american thoracic society clinical practice guideline［J］.Am J Respir Crit Care Med， 2026，212（1）：24-44.
［13］ 杨仕容，陈兰，汪江，等.非人工气道患者痰培养标本规范化采集管理的效果研究［J］. 护士进修杂志，2022，37（18）：1685-1688.
［14］ 吴燕廷，宋燕芹.纤维支气管镜联合肺泡灌洗术治疗重症社区获得性肺炎疗效观察［J］.海南医学，2021，32（14）：1814-1817.
［15］ 廖毓香，朱水泉，伍桂雄.宏基因二代测序技术在社区获得性肺炎病原体检测中的应用进展［J］.检验医学与临床，2024，21（14）：2131-2134，2144.
［16］ 顾伟，郭伟.从初始经验性抗感染药物使用看《中国老年社区获得性肺炎急诊诊疗专家共识》［J］.中华急诊医学杂志，2024，33（5）：720-723.
［17］ 国家卫生健康委员会．临床微生物学检验标本的采集和转运：WS/T 640-2018［S］.北京：中国标准出版社，2018．
［18］ 全球华人临床微生物暨感染学会专家组.成人门急诊急性呼吸道感染诊治与防控专家共识［J］.中华传染病杂志，2024，42（6）：321-337.
［19］ 中国宏基因组学第二代测序技术检测感染病原体的临床应用专家共识［J］.中华传染病杂志，2020，38（11）：681-689.
［20］ 冯素枝，焦岩，王平，等.CEA、FDP、CRP及D-二聚体在重症社区获得性肺炎中的水平变化及其对短期预后的预测价值［J］.热带医学杂志，2020，20（8）：1048-1051.
［21］ Carbonell R， Moreno G， Martín-Loeches I， et al. The role of biomarkers in influenza and COVID-19 community-acquired pneumonia in adults［J］.Antibiotics （Basel）， 2023，12（1）：161.
［22］ Piqueras M， González-Jiménez P， Latorre A， et al. Persistent systemic interleukin-6 elevation after community-acquired pneumonia is associated with one-year mortality［J］.Respir Res， 2025，26（1）：316.
［23］ Zhang Litao， Li Yanpeng， Lv Chang， et al. Predictive value of arterial blood lactate/serum albumin ratio for myocardial injury in elderly patients with severe community-acquired pneumonia［J］.Medicine （Baltimore）， 2022，101（4）：e28739.
［24］ Dinh A， Barbier F， Bedos JP， et al. Update of guidelines for management of community acquired pneumonia in adults by the French Infectious Disease Society （SPILF） and the French-speaking Society of Respiratory Diseases （SPLF）. Endorsed by the French Intensive Care Society （SRLF）， the French Microbiology Society （SFM）， the French Radiology Society （SFR） and the French Emergency Society （SFMU）［J］.Respir Med and Res， 2025，87：101161.
［25］ 李晶，程清，丁敏，等.CURB-65评分联合S100A8可预测老年社区获得性肺炎患者住院死亡风险［J］.内科急危重症杂志，2024，30（5）：407-411.
［26］ Alyami SMA， Alzomor O， Hassan IS， et al. The Saudi Thoracic Society evidence-based guidelines for the diagnosis and management of community-acquired pneumonia in children and adults［J］.Ann Thorac Med， 2025，20（4）：195-212.
［27］ 韶月，张黎川.社区获得性肺炎初始治疗失败的评估与处理进展［J］.中国急救医学，2022，42（2）：180-185.
［28］ Martin-Loeches I， Torres A， Nagavci B， et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia［J］.Intensive Care Med， 2023，49（6）：615-632.
［29］ Ramirez JA.General approach to immunocompromised patients with pneumonia： insights from the latest consensus documents［J］.Semin Respir Crit Care Med， 2026，47（2）：184-189.
［30］ 李燕菊，冯英，周晶晶，等.新疆某医院老年社区获得性肺炎住院患者抗菌药物使用情况调查［J］.河北医药，2022，44（22）：3496-3499，3503.
［31］ Flateau C， Dinia M， Raulet N， et al. Does a 5-day course of antibiotics in elderly patients with community-acquired pneumonia achieve the established criteria of clinical stability？［J］.Infect Dis Now， 2021，51（4）：377-379.
［32］ Zhang Liyun， Xu Xiaoqing， Badawy S， et al. A review： effects of macrolides on CYP450 enzymes［J］.Curr Drug Metab， 2020，21（12）：928-937.
［33］ 冯会.基于肾功能指标的动态监测对万古霉素治疗老年患者MRSA肺炎的疗效和安全性评价的影响［J］.抗感染药学，2021，18（4）：483-487.
［34］ 金阳宏，廉姜芳.氟喹诺酮类抗菌药物致获得性长QT综合征的研究进展［J］.心电与循环，2025，44（2）：220-224.
［35］ 邵微豪，韩雨婕，殷瑜，等.基于斑马鱼模型的4种氨基糖苷类药物的耳肾毒性比较［J］.中国医药工业杂志，2021，52（7）：934-939.
/
| 〈 |
|
〉 |